Roche's Phase III IMpower133 trial has met its co-primary endpoints in extensive-stage small cell lung cancer patients, adding to growing evidence backing use of Tecentriq-based combinations to treat different types of advanced lung cancer.
IMpower133's first interim analysis showed that combining Tecentriq (atezolizumab) with chemotherapy helped people with extensive-stage small cell lung cancer live significantly longer and reduced